For the roughly 1 billion people worldwide who live with migraine, the path to effective management is often a frustrating loop of symptom diaries, specialist waitlists, and trial-and-error medication. Migrevention, a Tallinn-based startup founded in 2020, is betting that entire loop can be digitized. The company has built what it calls the world's first fully digital headache clinic, a platform anchored by a Class I medical device app for patient diaries, self-monitoring, and asynchronous nurse counseling [Invest in Estonia, Jan 2022]. Its goal is not just to track pain, but to replace the episodic, in-person clinic visit with continuous, evidence-based care.
The Wedge of the Digital Diary
The company's initial wedge is the headache diary, a cornerstone of neurological diagnosis that is notoriously difficult for patients to maintain accurately on paper. Migrevention's app formalizes this process, structuring data collection for conditions like migraine and tension-type headache. This digital diary feeds a provider-facing dashboard, giving clinicians a longitudinal view of a patient's triggers, frequency, and medication use. The platform also includes a chat function connecting patients directly to a nurse for guidance, creating an always-on layer of support between appointments. This model, the founders argue, enables care that is ten times more efficient than conventional management [Invest in Estonia, Jan 2022].
A Clinical Bet on European Soil
Migrevention's approach is being tested in a formal clinical setting. The company is partnered with Tartu University Hospital in Estonia for an ongoing clinical intervention study, comparing its digitally delivered treatment protocol against conventional care [Invest in Estonia, Jan 2022]. This study, detailed in a protocol published in PLOS Digital Health, is a critical step. For a digital therapeutic aiming to be taken seriously by neurologists and health systems, peer-reviewed evidence of non-inferiority or superiority is the ultimate currency. The Estonian location provides a strategic advantage, operating within a digitally advanced national health system that may be more receptive to integrated virtual care models.
The Founders and the Funding
The startup was founded by a five-person team blending clinical, operational, and technical expertise. CEO Katrina Laks leads the venture, with Triinu Niiberg-Pikksööt as CFO and Karl Käis as CTO. The clinical backbone is provided by Chief Scientific Officer Mark Braschinsky, a lecturer and neurologist at the University of Tartu, who emphasizes evidence-based multimodal treatment [Health Founders, ~2021]. This clinical co-founder model is common in digital health, aiming to bridge the gap between software development and medical rigor.
To fund its initial build and clinical study, Migrevention closed a €355,000 pre-seed round in January 2022. The round was led by angel investor Dag Nurm and included participation from StartSmart CEE, the Challenger Accelerator, and the Estonian competition Ajujaht [Invest in Estonia, Jan 2022]. According to PitchBook data, the company's total disclosed funding stands at approximately $737,000, inclusive of accelerator support.
| Role | Name | Note |
|---|---|---|
| CEO | Katrina Laks | Leads the company. |
| CFO | Triinu Niiberg-Pikksööt | Manages financial operations. |
| CTO | Karl Käis | Leads technical development. |
| CSO | Mark Braschinsky | Neurologist and lecturer at University of Tartu. |
| Co-Founder | Einar Roosileht | Co-founding team member. |
Navigating a Crowded Self-Care Landscape
The primary challenge for Migrevention is differentiation in a market flooded with consumer-facing headache tracking apps. Competitors like the popular Migraine Buddy offer extensive symptom logging and community features, while others like Curelator focus on identifying personal triggers. Migrevention's rebuttal rests on its regulated status as a Class I medical device and its closed-loop B2B2C model, which is designed to be prescribed or recommended by a healthcare provider and integrated into a care plan. The company is not just selling self-help, it is selling a clinical tool for the healthcare system.
However, this path is fraught with the classic hurdles of digital health adoption:
- Clinical proof. The ongoing study at Tartu University Hospital must yield positive, publishable results to build credibility with the broader medical community.
- Commercial integration. The platform must demonstrate it can seamlessly fit into the workflows of busy neurology practices and be reimbursed by insurers or health systems.
- Patient engagement. It must prove that its digital tool sustains patient use over the long term, beyond the initial novelty, to deliver improved outcomes.
Success depends on moving beyond being a better diary to becoming an indispensable component of standard neurological care.
The Standard of Care Today
For a patient newly diagnosed with migraine, the current standard of care is often fragmented and passive. It typically begins with a paper diary, followed by waits for specialist appointments that can span months. Treatment is frequently medication-centric, with adjustments made reactively based on infrequent clinic check-ins. Patient education and behavioral strategies, which are crucial for management, are often compressed into brief consultations. Migrevention's bet is that by digitizing and continuousizing this process,shifting from episodic intervention to continuous management,patients can achieve better control faster, and healthcare systems can allocate specialist time more effectively. The company has also committed to donating 5% of its yearly revenue to migraine nonprofits and research, a gesture aligning its commercial goals with the patient community it serves [Health Founders, ~2021].
Sources
- [Invest in Estonia, Jan 2022] Estonian startup Migrevention builds a digital clinic to save you from headache | https://investinestonia.com/estonian-startup-migrevention-builds-a-digital-clinic-to-save-you-from-headache/
- [Health Founders, ~2021] Meet the Founders: Migrevention | https://healthfounders.ee/migrevention/
- [PLOS Digital Health, Unknown] Implementing a digital solution for patients with migraine,Developing a methodology for comparing digitally delivered treatment with conventional treatment: A study protocol | https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0000295
- [PitchBook, Unknown] Migrevention Company Profile | https://pitchbook.com/profiles/company/489707-56